SIRPA and neoplasm: To investigate tumor cell responsiveness during immunotherapy, established murine MC38 tumors were treated with mutant SIRPα- Fc (hIgG1) fusion protein (CV-1)49,50, a high-affinity reagent for CD47 blockade or control hIgG.